Periostin secreted by cancer-associated fibroblasts promotes cancer progression 
and drug resistance in non-small cell lung cancer

Takatsu, Fumiaki; Suzawa, Ken; Tomida, Shuta; Thu, Yin Min; Sakaguchi, Masakiyo; Toji, Tomohiro; Ohki, Masayoshi; Tsudaka, Shimpei; Date, Keiichi; Matsuda, Naoki; Iwata, Kazuma; Zhu, Yidan; Nakata, Kentaro; Shien, Kazuhiko; Yamamoto, Hiromasa; Nakayama, Akiko; Okazaki, Mikio; Sugimoto, Seiichiro; Toyooka, Shinichi

doi:10.1007/s00109-023-02384-7

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer

MPS-Authors

/persons/resource/persons239386

Nakayama, Akiko
Pharmacology, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Takatsu, F., Suzawa, K., Tomida, S., Thu, Y. M., Sakaguchi, M., Toji, T., et al. (2023). Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer. JOURNAL OF MOLECULAR MEDICINE-JMM. doi:10.1007/s00109-023-02384-7.

Cite as: https://hdl.handle.net/21.11116/0000-000D-E795-6

Abstract

Cancer-associated fibroblasts (CAFs) are important components in the tumor microenvironment, and we sought to identify effective therapeutic targets in CAFs for non-small cell lung cancer (NSCLC). In this study, we established fibroblast cell lines from the cancerous and non-cancerous parts of surgical lung specimens from patients with NSCLC and evaluated the differences in behaviors towards NSCLC cells. RNA sequencing analysis was performed to investigate the differentially expressed genes between normal fibroblasts (NFs) and CAFs, and we identified that the expression of periostin (POSTN), which is known to be overexpressed in various solid tumors and promote cancer progression, was significantly higher in CAFs than in NFs. POSTN increased cell proliferation via NSCLC cells' ERK pathway activation and induced epithelial-mesenchymal transition (EMT), which improved migration in vitro. In addition, POSTN knockdown in CAFs suppressed these effects, and in vivo experiments demonstrated that the POSTN knockdown improved the sensitivity of EGFR-mutant NSCLC cells for osimertinib treatment. Collectively, our results showed that CAF-derived POSTN is involved in tumor growth, migration, EMT induction, and drug resistance in NSCLC. Targeting CAF-secreted POSTN could be a potential therapeutic strategy for NSCLC.